Cellmover
Pre-clinical immunotherapy company developing intracellular biologics to modulate T cell and NK cell function in the tumor microenvironment. The organization maintains a pipeline of three lead preclinical projects and conducts nanobody and peptide discovery, production and lead optimization from facilities based at incubators in Oslo.
Industries
biotechnology
medical
therapeutics
Products
Three preclinical intracellular biologic drug candidates
A pipeline of three lead projects (intracellular biologic candidates) targeting intracellular proteins in immune cells, advanced through discovery, lead optimization and preclinical stages.
Three preclinical intracellular biologic drug candidates
A pipeline of three lead projects (intracellular biologic candidates) targeting intracellular proteins in immune cells, advanced through discovery, lead optimization and preclinical stages.
Services
Preclinical development of intracellular biologic therapeutics
Discovery, lead optimization and preclinical advancement of intracellular nanobody- and peptide-based biologic candidates intended to modulate immune cell function for cancer therapy.
Preclinical development of intracellular biologic therapeutics
Discovery, lead optimization and preclinical advancement of intracellular nanobody- and peptide-based biologic candidates intended to modulate immune cell function for cancer therapy.
Expertise Areas
- Preclinical drug development
- Nanobody and peptide therapeutics
- Intracellular biologics
- Protein expression and purification
Key Technologies
- Nanobody libraries
- Peptide therapeutics
- Intracellular biologic modalities
- Protein expression and purification